The Return on Investment of Scaling Tuberculosis Screening and Preventive Treatment: A Modelling Study in Brazil, Georgia, Kenya, and South Africa
Authors: Vesga Juan F. , Mohamed Mona Salaheldin , Shandal Monica , Jabbour Elias , Lomtadze Nino , Kubjane Mmamapudi , Trajman Anete , Meyer-Rath Gesine , Avaliani Zaza , Rotich Wesley , Mwai Daniel , Croda Julio , Mathema Hlengani T. , Kathure Immaculate , Pola Rhoda , Dockhorn Costa Fernanda , Ndjeka Norbert O. , Danelia Maka , Tonini Maiko L. , Solomonia Nelly , Pelissari Daniele M. , Falzon Dennis , Miller Cecily , Baena Ines Garcia , Arinaminpathy Nimalan , Schwartzman Kevin , Den Boon Saskia , Campbell Jonathon R. 
Published: March 2024

SummaryBackgroundClosing the tuberculosis diagnostic gap and scaling-up tuberculosis preventive treatment (TPT) are two major global priorities to end the tuberculosis epidemic. To help support these efforts, we modeled the impact and return-on-investment (ROI) of a comprehensive intervention to improve tuberculosis screening and prevention in Brazil, Georgia, Kenya, and South Africa—four distinct epidemiological settings.MethodsWe worked with national tuberculosis programmes (NTP) in each country to define a set of interventions (“the intervention package”) related to tuberculosis screening and TPT in three priority populations: people with HIV, household contacts, and a country-defined high-risk population. We developed transmission models calibrated to tuberculosis epidemiology for each country, and collated cost data related to tuberculosis-related activities and patient costs in 2023 $USD. We compared the intervention package without and with TPT scaled-up to reach priority populations to a status quo scenario based on projected tuberculosis epidemiology over a 27-year time horizon (2024-2050). Outcomes were health system and societal costs, number of tuberculosis episodes, tuberculosis deaths, and disability adjusted life years (DALYs). We performed 1000 simulations and calculated the mean and 95% uncertainty range (95%UR) difference in outcomes between the intervention package and the status quo. We calculated the health system cost per DALY averted and societal return on the health system investment for each country. We did not discount costs or outcomes in the base scenario.FindingsUnder the status quo, by 2050, tuberculosis incidence is projected to be 39 (95%UR 37-43), 34 (24-50), 204 (186-255), and 208 (124-293) per 100,000 population in Brazil, Georgia, Kenya, and South Africa, respectively. Implementing the intervention package without TPT is projected to reduce tuberculosis incidence by 9.6% (95%UR 9.3-10), 14.4% (11-19.6), 30.3% (29-33.1), and 22.7% (19.4-27.2) in Brazil, Georgia, Kenya, and South Africa, respectively, by 2050. The addition of TPT is projected to further reduce tuberculosis incidence by 9.5% (95%UR 9.3-9.8), 10.9% (9.8-12.3), 19.2% (17.6-20.1), and 13.1% (11.2-14.4%). From the health system perspective, the incremental cost per DALY averted of the intervention package is $771 in Brazil, $1402 in Georgia, $521 in Kenya, and $163 in South Africa. The societal return per $1 invested by the health system is projected to be $10.80, $3.70, $27.40, and $39.00 in Brazil, Georgia, Kenya, and South Africa, respectively.InterpretationScaling-up interventions related to tuberculosis screening and TPT in priority populations is projected to substantially reduce tuberculosis incidence and provide large returns on investment.FundingWorld Health Organization.